Clinical trial
A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2…
NCT00481663 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00481663 |
|---|---|
| Title | A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014) |
| Official title | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Finding Study of Once-Daily Dosing of Sitaglipin (MK-0431) in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type II Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Sitagliptin, Placebo to sitagliptin, Metformin, Rescue |
| Enrollment | 555 |
| Start date | Aug 19, 2003 |
| Primary completion | Jul 21, 2004 |
| Completion | May 14, 2006 |
| First posted | Jun 4, 2007 |
| Last update posted | Apr 4, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: